Cytokinetics to Hold Annual Meeting of Stockholders
(Thomson Reuters ONE) -
SOUTH SAN FRANCISCO, Calif., May 13, 2015 (GLOBE NEWSWIRE) -- Cytokinetics,
Incorporated (Nasdaq:CYTK) announced today that its Annual Meeting of
Stockholders will be held on Wednesday, May 20, 2015 at 10:30 AM Pacific Time at
the Embassy Suites Hotel, located at 250 Gateway Boulevard in South San
Francisco, CA. Robert I. Blum, President and Chief Executive Officer, is
scheduled to present an overview of Cytokinetics' performance.
Interested parties may access the live audio webcast of this presentation and
replay by visiting the Investor Relations section of the Cytokinetics website at
www.cytokinetics.com. The live conference call may also be accessed by dialing
(866) 999-CYTK (2985) (United States and Canada) or (706) 679-3078
(international) and typing in the passcode 34785263. The webcast will be
available via Cytokinetics' website for one week following the event. The replay
of the audiocast will be available via telephone from May 20, 2015 at 1:30 PM
Pacific Time until May 27, 2015 by dialing (855) 859-2056 (United States and
Canada) or (404) 537-3406 (international) and typing in the passcode 34785263.
About Cytokinetics
Cytokinetics is a clinical-stage biopharmaceutical company focused on the
discovery and development of novel small molecule therapeutics that modulate
muscle function for the potential treatment of serious diseases and medical
conditions. Cytokinetics is developing tirasemtiv, a fast skeletal muscle
activator, as a potential treatment for amyotrophic lateral sclerosis (ALS).
Tirasemtiv has been granted orphan drug designation and fast track status by the
U.S. Food and Drug Administration and orphan medicinal product designation by
the European Medicines Agency for the potential treatment of ALS. Cytokinetics
is collaborating with Amgen Inc. to develop omecamtiv mecarbil, a cardiac muscle
activator, for the potential treatment of heart failure. Cytokinetics is
collaborating with Astellas Pharma Inc. to develop CK-2127107, a fast skeletal
muscle activator, for the potential treatment of spinal muscular atrophy. Amgen
holds an exclusive license worldwide to develop and commercialize omecamtiv
mecarbil and Astellas holds an exclusive license worldwide to develop and
commercialize CK-2127107. Both licenses are subject to Cytokinetics' specified
development and commercialization participation rights. All of these drug
candidates have arisen from Cytokinetics' muscle biology focused research
activities and are directed towards the cytoskeleton. The cytoskeleton is a
complex biological infrastructure that plays a fundamental role within every
human cell. Additional information about Cytokinetics can be obtained at
http://www.cytokinetics.com/.
This press release contains forward-looking statements for purposes of the
Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics
disclaims any intent or obligation to update these forward-looking statements,
and claims the protection of the Act's safe harbor for forward-looking
statements. Examples of such statements include, but are not limited to,
statements relating to planned presentations, and the properties and potential
benefits of Cytokinetics' drug candidates and potential drug candidates. Such
statements are based on management's current expectations, but actual results
may differ materially due to various risks and uncertainties, including, but not
limited to, potential difficulties or delays in the development, testing,
regulatory approval and production of Cytokinetics' drug candidates and
potential drug candidates that could slow or prevent clinical development or
product approval, including risks that current and past results of clinical
trials or preclinical studies may not be indicative of future clinical trials
results and that Cytokinetics' drug candidates and potential drug candidates may
have unexpected adverse side effects or inadequate therapeutic efficacy. For
further information regarding these and other risks related to Cytokinetics'
business, investors should consult Cytokinetics' filings with the Securities and
Exchange Commission.
CONTACT: Cytokinetics, Incorporated
Joanna L. Goldstein (Investors & Media)
(650) 624-3000
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Cytokinetics via GlobeNewswire
[HUG#1921614]
Unternehmensinformation / Kurzprofil:
Datum: 13.05.2015 - 22:00 Uhr
Sprache: Deutsch
News-ID 393237
Anzahl Zeichen: 5166
contact information:
Town:
South San Francisco
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 154 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Cytokinetics to Hold Annual Meeting of Stockholders"
steht unter der journalistisch-redaktionellen Verantwortung von
Cytokinetics (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
